Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credit: iStock
India has joined the Global Antibiotic Research and Development Partnership (GARDP)-led NeoSep1 clinical trial, a landmark international study evaluating new antibiotic treatments for newborns with drug-resistant sepsis.
Sepsis is the second leading cause of neonatal mortality in India after prematurity and low birth weight, accounting for an estimated 30–40 per cent of all newborn deaths.
The NeoSep1 trial began in India with the first baby enrolled at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) in Puducherry, followed by Pt. B.D. Sharma PGIMS in Rohtak. Lokmanya Tilak Municipal Medical College and General Hospital in Mumbai is also expected to begin enrolling newborns soon.
"Every day doctors face the heartbreaking reality of losing babies to sepsis due to lack of safe and effective treatments," said Dr Nishad Plakkal, Principal Investigator of the NeoSep1 trial in India and Associate Dean (Research) and Professor and Head of the Department of Neonatology at JIPMER.
"Having the right antibiotics at the right dose can tip the balance between life and death. This trial offers hope to change that," Plakkal added.
"The trial will give neonatologists new tools, and give babies with sepsis a fighting chance at life," said Sally Ellis, who leads GARDP's Children's Antibiotics Program.
Also read:US Woman Nearly Died After Brushing Off Sepsis Symptoms As Flu
According to Ellis, newborns are particularly vulnerable to life-threatening sepsis because of their underdeveloped immune systems.
The growing burden of antibiotic resistance in low- and middle-income countries (LMICs) has further worsened the problem by reducing the effectiveness of standard treatments. Studies have reported extremely high resistance to the combination of ampicillin and gentamicin, the antibiotic regimen currently recommended by the World Health Organization for the initial treatment of neonatal sepsis.
"Today, we stand at a tipping point. The antibiotics for newborns that we have relied on for decades are failing against resistant infections in many hospital settings," Ellis said.
Read More: Andhra Pradesh To Launch Rare Disease Policy, Expand Universal Newborn Screening
An estimated 3 million newborns develop sepsis every year. The condition occurs when the body's response to an infection triggers widespread inflammation, potentially leading to tissue damage, organ failure, and death. More than 90% of neonatal sepsis deaths occur in low- and middle-income countries.
The NeoSep1 trial aims to identify safe and effective antibiotic regimens that can reduce deaths caused by drug-resistant neonatal sepsis.
The first phase of the study, conducted in South Africa and Kenya in 2023, validated the appropriate doses of fosfomycin and flomoxef when used in combination with other antibiotics in newborns.
The second phase is using a Personalised Randomised Controlled Trial (PRACTical) design to evaluate and rank multiple antibiotic regimens for newborns with sepsis. The approach is expected to help clinicians choose the most effective treatments based on local patterns of antibiotic resistance while also informing future national and international treatment guidelines.
The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028.
Along with India, newborns have already been enrolled in Ghana, Kenya, and South Africa. Hospitals in Vietnam, Pakistan, Malaysia, Bangladesh, and Uganda are also expected to join the study.
Sepsis is a life-threatening reaction to an infection that harms the immune system, tissues, and organs. It can lead to organ failure or death if not treated urgently, according to the Cleveland Clinic.
According to Sepsis Alliance, the acronym TIME can help people recognize potential warning signs of sepsis and seek urgent medical care.
T — Temperature: Body temperature is unusually high or low.
I — Infection: Signs or symptoms of an infection are present.
M — Mental Decline: Confusion, excessive sleepiness, or difficulty waking up.
E — Extremely Ill: Severe pain, extreme discomfort, or shortness of breath.
Credits: Canva
The highly pathogenic H5N1 bird flu virus has now spread to a second Australian state. Less than a week after it was first identified in two seabirds in Western Australia, authorities have confirmed another case in South Australia.
For the general public, the health risk remains low. Experts say people who don't regularly handle infected birds or animals are unlikely to contract the virus. However, Australia's poultry industry is treating the situation with extreme caution.
If the virus were to reach commercial poultry farms, the consequences could be severe. Millions of chickens and other birds could either die from the disease or be culled to stop it from spreading. Such an outbreak could also trigger export restrictions on Australian poultry products and leave farmers facing massive cleanup and recovery costs, even with government assistance.
So far, there is no evidence that H5N1 has entered any commercial poultry farms or Australia's native wild bird populations. The confirmed cases have been limited to wild seabirds.
Even so, poultry producers across the country—particularly in Western Australia and South Australia—are already tightening biosecurity measures to reduce the risk of the virus reaching their flocks.
Also Read: New Oral GLP-1 Pill Delivers Major Weight Loss In Just 36 Weeks
Australia's largest poultry producer, Inghams, has restricted access to its Western Australian farms, allowing only essential personnel to enter. The company has also requested permission from the federal government's Chief Veterinary Officer to temporarily move its free-range birds indoors. The aim is to reduce any contact between domestic poultry and wild birds, which are considered the most likely source of infection.
These additional precautions build on the strict biosecurity rules already followed by the poultry industry. Farm visits are kept to a minimum, employees are generally prohibited from keeping backyard chickens or other birds at home, and workers are discouraged from moving between different poultry facilities within a short period. Many farms also require staff to shower before entering, change into company-issued clothing, and follow rigorous hygiene procedures. Measures to keep wild birds away and control rodents and insects are also a standard part of farm management.
The H5N1 strain is particularly deadly for chickens, as well as turkeys and quail. Ducks can also become infected, but they present a different challenge because they may carry and spread the virus without showing obvious signs of illness, making them especially difficult to monitor.
Until now, Australia was the only continent where the H5N1 strain, the highly contagious strain of H5 bird flu, had not been detected. Although the virus has circulated across Asia since the 1990s and reached Antarctica in 2024, Australia had remained unaffected.
According to Dr Michelle Wille, ARC Future Fellow at the University of Melbourne, Australia's unique bird migration patterns likely delayed the virus's arrival.
"There are no duck species which routinely migrate between Australia and Asia, nor are there ducks that migrate through Antarctica," Wille wrote in The Conversation.
However, evidence suggests other seabirds—including gulls, skuas and giant petrels—may have helped carry the virus over long distances across Antarctica and subantarctic regions, eventually bringing it closer to Australia, he said.
As per the latest update, Australian scientists believe that the H5 bird flu strain killed more than 13,000 elephant seal pups after infecting a breeding colony on the remote Heard and McDonald Islands, one of Australia's external territories in the sub-Antarctic.
Credit: Instagram
American supermodel Bella Hadid has opened up about the mental toll of living with Lyme disease, a chronic illness she has battled for years.
Bella Hadid was diagnosed with Lyme disease in 2013 and has endured an ongoing battle with physical pain, extreme fatigue, brain fog, and associated depression.
In a series of Instagram Stories, the 29-year-old model shared about the daily hardships and emotional toll of recurring health flare-ups despite trying various treatment protocols.
The supermodel said it is "intimidating" to explain her symptoms of pain, exhaustion, fatigue, anxiety, brain fog, infections and trauma, and how they lead "to severe isolation and depression, especially over long periods of time," People.com reported.
"Especially when you try anything you can," she said, adding that she has read books and personal stories to better understand her symptoms, yet still experiences setbacks.
"You demand answers that no one can find. You fight. You finally have a few good days. You think you've found the right protocol, the right routine, the right treatment... and then a flare-up comes back and all of a sudden nothing feels certain again."
Hadid said flare-ups of the chronic illness often force her to cancel plans.
"You wake up with anxiety already living in your body," Hadid wrote.
"Physical pain before your feet even touch the floor....And somehow, still have to find the strength to move through another day in a body and mind that are completely exhausted."
The model said she has learned to mask her feelings.
"Sometimes it feels like unless you've lived something like this, or loved someone who has, it's impossible to fully understand."
She also reminded followers facing similar struggles that "there is light, even if you can't see it today... There is hope," before sharing a message she often tells herself during difficult times.
"As so many have said..I have to remind myself that healing isn't linear...I believe God puts before us, somehow, only what we are capable of carrying, even when we don't understand why at the time," she wrote, saying there's a "deeper purpose to all things in life."
Hadid acknowledged that although it is hard, she believes "every hardship leaves us with a lesson, a deeper compassion, or a strength we never knew we had."
According to the US Centers for Disease Control and Prevention (CDC), Lyme disease is a bacterial infection spread to people through the bite of infected blacklegged ticks.
Every year, an estimated 31 million people in the United States are bitten by a tick.
Lyme disease is the most common tick-borne disease in the United States, with an estimated 476,000 patients treated for Lyme each year.
Typical symptoms include:
The best defense against Lyme disease is to prevent tick bites. This will reduce your risk of other tickborne diseases as well.
What to do after a tick bite:
© 2024 Bennett, Coleman & Company Limited